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Abstract 
Background 
In areas where visceral leishmaniasis (VL) and malaria are co-endemic, co-infections are 
common. Clinical implications range from potential diagnostic delay to increased disease-
related morbidity as compared to VL patients. Nevertheless, public awareness of the disease 
remains limited. In VL-endemic areas with unstable and seasonal malaria, vulnerability to the 
disease persists through all age-groups, suggesting that in these populations, malaria may 
easily co-occur with VL, with potentially severe clinical effects. 
Methods 
A retrospective case–control study was performed using medical records of VL patients 
admitted to Tabarakallah and Gedarif Teaching Hospitals (Gedarif State) and Al`Azaza kala-
azar Clinic (Sennar State), Sudan (2005–2010). Patients positively diagnosed with VL and 
malaria were identified as cases and VL patients without microscopy-detectable malaria as 
controls. Associations between patient characteristics and the occurrence of the co-infection 
were investigated using logistic regression analysis. Confirmation of epidemiological 
outcomes was obtained with an independently collected dataset, composed by Médecins Sans 
Frontières (MSF) at Um-el-Kher and Kassab Hospitals, Gedarif State (1998). 
Results 
The prevalence of malaria co-infection among VL surveyed patients ranged from 3.8 to 
60.8%, with a median of 26.2%. Co-infected patients presented at hospital with deteriorated 
clinical pictures. Emaciation (Odds Ratio (OR): 2.46; 95% Confidence Interval (95%CI): 
1.72-3.50), jaundice (OR: 2.52; 95%CI: 1.04-6.09) and moderate anemia (OR: 1.58; 95%CI: 
1.10-2.28) were found to be positively associated with the co-infection, while severity of 
splenomegaly (OR: 0.53; 95%CI: 0.35-0.81) and, to a less extent, hepatomegaly (OR: 0.52; 
95%CI: 0.27-1.01) appeared to be reduced by concomitant VL and malaria. The in-hospital 
case-fatality rates did not significantly differ between co- and mono-infected patients (OR: 
1.13; 95% CI: 0.59-2.17). Conversely, a significantly increased mortality rate (OR: 4.38; 95% 
CI: 1.83-10.48) was observed by MSF amongst co-infected patients enrolled at Um-el-Kher 
and Kassab Hospitals, who also suffered an enhanced risk of severe anemia (OR: 3.44; 95% 
CI: 1.68-7.02) compared to VL mono-infections. 
Conclusions 
In endemic VL areas with unstable seasonal malaria, like eastern Sudan, VL patients are 
highly exposed to the risk of developing concomitant malaria. Prompt diagnosis and effective 
treatment of malaria are essential to ensure that its co-infection does not result into poor 
prognoses. 
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Background 
In areas where malaria is co-endemic with visceral leishmaniasis (VL), co-infections with 
both diseases are common [1]. Previous observations performed through cohorts of VL 
patients report the occurrence of this co-infection across major VL hot spots [2-5], with 
prevalence ranging from 31% in Sudan [6] to 1.2% in Bangladesh [7]. At Amudat Hospital, 
Uganda, where nearly one out of five VL-confirmed patients hospitalized between 2000 and 
2006 was co-diagnosed with malaria, concomitant malaria was shown to exacerbate 
symptoms of VL patients, though with no implications for their prognosis [1]. Children under 
10 years of age, notoriously more vulnerable to both malaria and VL, exhibited a twofold 
higher risk of being co-infected compared to adults. The clinical relevance of the VL-malaria 
co-morbidity, as attested by its frequency and severity at Amudat Hospital, highlights the 
risks associated with disease co-endemicity and suggests that other malaria- and VL-endemic 
areas may experience similar co-infection burdens. 
Of the 30,000 to 50,000 annual VL cases estimated in East Africa, the second largest VL 
focus after South-Asia, half as many (15,700 to 30,300) are thought to occur in Sudan [8,9]. 
Hyper-endemic foci are located in the eastern part of the country, stretching from the White 
Nile in the west to the Ethiopian border in the east, and from Kassala State in the north across 
the border of Southern Sudan up to Upper Nile State in the south [10]. Here, the disease has 
been reported since the early 1900s [11-13], but it is in the past 30 years that it has reached 
dramatic proportions, resulting in recurrent epidemics which have claimed hundreds of 
thousands of lives [14-16]. Currently, Gedarif State in Eastern State, together with the region 
of Sennar and Singa in Central State, accounts for the vast majority of VL cases in Sudan 
[17]. The distribution of the disease within these areas is wide, erratic and variable, with 
highly endemic clusters situated near the banks of the Blue Nile River and its tributaries 
(Dinder, Rahad and Atbara Rivers) and the Dinder National Park [18-22]. Here, during the 
outbreaks that cyclically recur (every 7–10 years), the disease can reach incidences of >50 
cases per 1000 per year [22]. Diagnostics and treatment services are available at several 
governmental hospitals and rural dispensaries. However, due to the high cost of treatment, 
many cases have been referred to Médecins sans Frontières-Holland (MSF-H), whose 
activities at Um-el-Kher and Kassab VL treatment centers have resulted in more than 24,000 
VL patients treated over the last hyper-endemic period (1996–2003) [17]. In the early 2000s, 
after an initial decline in the disease incidence, a new upsurge in the number of VL cases was 
recorded [9], leading to the establishment in January 2010 of a new VL ward (MSF-
Switzerland) at Tabarakallah Hospital. 
Unstable seasonal malaria, due to Plasmodium falciparum, prevails in most areas of Gedarif 
and Sennar States, where prevalence rates of 1.6% and 1.1%, respectively, were confirmed 
among the communities surveyed in 2009 [23]. This epidemiological pattern of malaria 
transmission considerably affects the age-related ability of local individuals to acquire 
immunity against clinical malaria, resulting into seasonal outbreaks that strike all age-groups, 
albeit with different incidences [24,25]. Subclinical infections are often harbored throughout 
the dry season, resulting into semi-immunity which ultimately develops within 2 to 3 decades 
[26]. Concomitant exposure of these individuals to Leishmania parasites may, therefore, have 
dramatic consequences on ability to control both infections, potentially resulting in an 
aggravated clinical picture. 
To describe the clinical impact of VL-malaria co-infections in patients with low malaria 
immunity, we investigated the epidemiology of VL-malaria co-infections in a VL endemic 
area characterized by unstable seasonal malaria. By surveying three strategically located 
hospitals, we obtained a semi-representative data collection of Gedarif and Sennar States 
(2005–2010), whereby the risk for local VL patients of acquiring a malaria co-infection was 
assessed. The high prevalence of this co-morbidity and its negative impact on patients’ 
clinical condition, as observed in this study, highlighted the existence of a clinically 
significant condition, whose life-threatening implication was indirectly confirmed by an 
independently collected dataset, gathered by MSF-H at Um-el-Kher and Kassab Hospitals, 
Gedarif State, in 1998. 
Methods 
Study area 
The study area lies in Sudan, between the Blue Nile River in the central region of Sennar 
State and the lower Atbara River, which borders Gedarif State in the northeast. The Rahad 
River and the Dinder River, both tributaries of the Blue Nile River, flow across the region 
with seasonal regime, marked by major floods during the rainy season (from June to October) 
and long periods of dry-off throughout the rest of the year. Al`Azaza kala-azar Clinic (Sennar 
State), Gedarif Teaching Hospital and Tabarakallah Hospital (Gedarif State) (Figure 1) were 
selected as treatment centers for conducting the survey. The hospitals encompass a VL-
dedicated ward, where diagnosis and treatment for VL are performed. Gedarif Teaching 
Hospital, situated in the city of Gedarif, receives patients from the town and surrounding 
areas. In addition, difficult clinical cases encountered at regional level are referred to the 
hospital, which therefore serves as Regional Reference Hospital. Al`Azaza kala-azar clinic, 
located along the Dinder River, in proximity to the Dinder National Park, is a rural hospital. 
Together with Gedarif Teaching Hospital, Kassab Hospital and 4 other health centers in 
Gedarif and Sennar States, the clinic received training and support from MSF-H, as part of a 
“restructuring program” (2001–2004) for improving local management of VL cases. 
Tabarakallah Hospital, located in the eastern Atbara region, 20 km south from the Atbara 
River, is a rural hospital which houses an MSF VL treatment center from January 2010. After 
departure of MSF-H from the region in 2004, many of the medical staff who worked with 
MSF in an independent Zakat (Islamic charity)-funded clinic in Tabarakallah, were employed 
by the hospital. 
Figure 1 Map of Gedarif and Sennar States, Sudan, indicating the study sites and 
neighboring villages. The study hospitals are shown with a star, while circles indicate 
neighboring cities and villages. 
Study design and population 
A retrospective case–control study was performed on patients positively diagnosed for VL. 
Patients with a laboratory-confirmed diagnosis of both VL and malaria at hospital admission 
or during hospitalization were identified as cases, while controls were patients similarly 
diagnosed with VL, whose blood smears tested negative for malaria. Laboratory-confirmation 
of VL was obtained either through microscopic examination of lymph node, bone marrow or 
spleen aspirates, or using serological tests, such as the direct agglutination test (DAT) (titer 
≥1:6400) and the rk39 antigen-based dipstick (Kalazar Detect Rapid Test®), in combination 
with the clinical case definition of the World Health Organization (WHO) [27]. Intensity of 
Leishmania infection in lymph node or bone marrow aspirates was categorized according to 
the WHO-recommended grading system [28,29]. Briefly, parasitaemias ranging from +1 to 
+4 were defined as smears containing 1–10 parasites in 1000, 100, 10 or 1 field, respectively, 
while 10–100 and >100 parasites per field indicated a parasitaemia of +5 and +6, 
respectively. Malaria was confirmed by microscopic examination of blood smears or by 
Rapid Diagnostic Tests (RDTs) (SD Bioline Malaria Ag P.f/P.v). Diagnosis of other 
concomitant diseases was based on clinical suspicion only. Clinical examination of patients 
included assessment of hemoglobin (Hb) levels (Lovibond method), spleen size (measured in 
the anterior axillary line to the furthest point during quiet breathing) and liver size (measured 
in midclavicular line during quiet breathing). Nutritional status, as determined by Weight-for-
High percentiles or Body Mass Index (BMI), was directly recorded. Standard treatment for 
all VL patients, including relapsing cases, consisted of generic sodium stibogluconate 
administered parenterally. For malaria, artemisinin derivatives (artemether or artesunate), as 
mono-therapy or in combination with sulfadoxine-pyrimethamine (SP) or lumefantrine, or 
alternatively quinine were administered as first-line treatment. Test of cure was regularly 
performed for VL, but not for malaria, by microscopy on lymph node or bone marrow 
aspirates. 
Data collection 
Medical records of patients hospitalized between January 2005 and December 2010 in the 
three hospitals, were retrospectively reviewed. Data from patients positively diagnosed with 
VL were collected manually, by using paper Case Record Forms (CRF) specially designed 
for the study. Data included patients’ demographic details, clinical signs and symptoms, test 
results, medical treatments and relative outcomes. Upon completion of the collection process, 
data were single-entered using SPSS 15.0 (SPSS Inc., Chicago, IL, USA) and Microsoft 
Excel softwares. 
Data analysis 
Descriptive analyses were conducted to examine the features of the overall study population 
and to assess prevalence and case-fatality rates of the co-infected patients. Statistical analysis 
was performed using SPSS 15.0 software. Characteristics of cases and controls were 
individually compared, using the Pearson Chi-square test or the Fisher Exact Probability test. 
Continuous variables were categorized in predefined groups: age (<5, 5–9, 10–19, 20–29 and 
≥30 years) based on malaria risk, spleen size (0–3 cm, 4–5 cm and ≥6 cm) by percentiles and 
anemia based on hemoglobin level (no-mild ≥7.3 g/dl, moderate 5.3-7.2 g/dl and severe <5,3 
g/dl). As only few patients (n = 22, 2.0%) were found to be non-anemic (Hb ≥11 g/dl), while 
the majority (n = 606, 55.1%) had mild anemia (Hb 7.3-10.9 g/dl), the groups with no and 
mild anemic patients were combined in one category, more truly representative of the patient 
set for anemia risk assessment. Seasonality of the co-infection was examined by categorizing 
hospital admissions during wet season (from June to October) or dry season (from November 
to May). Odds ratio (OR) with 95% confidence intervals (CI) were calculated to test whether 
a variable significantly differed between cases and controls. Multivariable logistic regression 
models were used to identify independent patients’ characteristics associated with the co-
infection. All variables with a P-value <0.10 in the univariate analyses were entered stepwise 
in the multivariate analysis, whose final model only comprised significant variables (P-value 
<0.05) and variables which significantly increased the model fit, as assessed by the −2 Log 
Likelihood test. 
MSF’s dataset 
Demographic and clinical data of VL patients enrolled in a clinical trial conducted by MSF-H 
at Um-el-Kher and Kassab Hospitals (1998) were analyzed for comparison with the survey 
outcomes. Both hospitals lie in Gedarif State (Figure 1), in proximity to the Rahad River and 
the Gedarif town, respectively, where prevalence of malaria and VL averages the rates 
characterizing the survey sites. The trial conducted by MSF aimed to compare efficacy and 
safety of branded versus generic sodium stibogluconate for the treatment of primary VL. 
Hence, the study population comprised patients with a laboratory-confirmed diagnosis of VL 
(DAT titer ≥1:6400 or demonstration of Leishmania on aspirates of spleen or lymph node) 
and no history of previous anti-leishmanial treatment. Microscopic search for malaria was 
also performed on all study subjects at enrollment. Treatment for VL consisted of either 
Pentostam or generic sodium stibogluconate given intramuscularly (20 mg/kg/day for 30 
days), while SP and quinine were administered as first-line treatment for uncomplicated and 
severe malaria, respectively. Using the same case–control definition as in the survey, 
descriptive and statistical analyses (Person Chi-square test) were performed to assess 
prevalence and mortality rates of the VL-malaria co-infection and to measure its association 
with explanatory variables. 
Ethical approval 
Data were collected as part of routine patient care, with no need for additional investigations. 
Data extraction from medical records was performed by anonymizing the information 
recorded in the CRFs. Ethical approval for the study was obtained from the Health 
Directorates of Gedarif and Sennar States (3rd January 2011) and from the Ethics Review 
Board of MSF (19th July 2012). 
Results 
Prevalence of VL-malaria co-infections in Gedarif and Sennar States (2005–
2010) 
A total of 1324 medical records reporting on VL-diagnosed patients hospitalized in Gedarif 
Teaching Hospital, Al`Azaza kala-azar Clinic and Tabarakallah Hospital during the study 
period were reviewed for the survey. Of these, 1295 reported on patients with a laboratory-
confirmed VL infection, who were included in the study, while the remaining 29 were 
excluded for lack of laboratory diagnostic evidence. Microscopy, mainly performed on lymph 
node (n = 848, 65.5%), bone marrow (n = 428, 33.1%) and/or spleen (n = 3, 0.2%) aspirates, 
was used for the diagnosis of VL. Serology was performed in 17 patients, 13 of whom were 
confirmed by DAT and 4 by rk39 antigen-based dipstick. Overall, 404 (31.2%) of the VL-
confirmed patients were co-diagnosed with malaria at hospital admission or during 
hospitalization. In all cases but one, in which diagnosis was established with an RDT, malaria 
was confirmed by microscopy. Stratification of the study population by hospital resulted into 
an unevenly distributed co-infection rate, with a prevalence of 3.8% in Gedarif Teaching 
Hospital (n = 18), followed by Tabarakallah Hospital (n = 84) and Al`Azaza kala-azar Clinic 
(n = 302) with 26.2% and 60.8%, respectively. With the exception of one P. vivax-infection, 
all malaria cases for which the Plasmodium species was determined, were attributed to P. 
falciparum (n = 396, 98.0%). 
Demographic and clinical features of VL-malaria co-infections in Gedarif and 
Sennar States (2005–2010) 
With a median age of 12 years (inter-quartile range 5–23 years), nearly three quarters of VL-
malaria co-infected patients were under 20 years old. Stratified by age, the percentage of 
cases was highest among children aged between 0 and 4 years (40.7%, n = 120/296) and 
progressively reduced until 29 years (27.0%, n = 50/185)(data not shown), indicating that the 
chance of detecting malaria in patients already diagnosed for VL declined as age increased. 
Residents of Sennar State appeared to be mostly stricken by the co-infection, particularly in 
the villages of Al`Azaza (28.0%), Om Bagraa (8.7%) and Jaldook (5.2%). Anemia 
(hemoglobin level <11 g/dl) was a hallmark of nearly all co- and mono-infected patients 
(91% and 79%, respectively), with most patients being diagnosed with mild or moderate 
anemia on hospital admission. Co-occurrence of malaria in VL patients resulted in increased 
severity of the anemia status, as shown by the decrease in median hemoglobin level (7.0 g/dl, 
inter-quartile range 6.5-8.0 g/dl for cases and 8.0 g/dl, 7.0-9.0 g/dl for controls). Despite most 
co- and mono-infected patients presented with enlarged spleen, frequency (92% for cases, 
95% for controls) and severity of splenomegaly (median spleen size below the costal margin 
4.0 cm, inter-quartile range 2.0-6.0 cm for cases and 5.0 cm, 2.0-8.0 cm for controls) 
appeared to be slightly reduced by concomitant malaria. 
In Al`Azaza kala-azar Clinic and Tabarakallah Hospital, most co-infections were detected 
among young boys (median age 9 and 10 years, inter-quartile range 3–23 years and 4–18 
years, respectively) (Table 1). In Gedarif Teaching Hospital, conversely, cases unlike 
controls mainly consisted of girls (55.6%, n = 10/176) (Table 1), although the difference 
appeared to be statistically not significant. Seasonal distribution of hospital admissions was 
similar in all the three hospitals, with most patients presenting at hospital during the long dry 
season (November-May). Co-occurrence of malaria in VL patients resulted in a sharper 
division between dry and wet season, particularly in Gedarif Teaching Hospital where 82.4% 
of all co-infected patients were hospitalized between November and May, emphasizing the 
peculiar time-trend of these co-infections (in these regions malaria usually occurs during or 
shortly after the rains, while VL clinical cases peak during the dry season). Finally, with a 
median disease duration of 12 days from the initial onset of symptoms, co-infected patients 
presented at Tabarakallah Hospital earlier than at Al`Azaza kala-azar Clinic (21 days) or 
Gedarif Teaching Hospital (30 days). 
Table 1 Characteristics of the overall VL population and VL-malaria co-infected 
patients, stratified by hospital, Sudan (2005–2010) 
Treatment center Gedarif Teaching 
Hospital 
Tabarakallah Hospital Al`Azaza Kala-azar Clinic 
 Total population Co-infected 
patients 
Total 
population 
Co-infected 
patients 
Total 
population 
Co-infected 
patients 
n (%) n (%) n (%) n (%) n (%) n (%) 
Number of patients 468 18 (3.8) 321 84 (26.2) 497 302 (60.8) 
Gender 456 18 321 84 497 302 
 Male  280 (61.4) 8 (44.4) 179 (55.8) 49 (58.3) 254 (51.1) 155 (51.3) 
 Female  176 (38.6) 10 (55.6) 142 (44.2) 35 (41.7) 243 (48.9) 147 (48.7) 
Age 440 15 321 84 492 301 
 Median (years)  14.0 13.0 10.0 10.0 9.0 9.0 
 (inter-quartile range)  (7.0-24.5) (9.0-29.0) (5.0-18.0) (4.2-17.7) (3.0-23.0) (3.0-23.0) 
 0-4 years  68 (15.5) 2 (13.3) 77 (24.0) 21 (29.8) 151 (30.7) 97 (32.2) 
 5-9 years  87 (19.8) 3 (20.0) 71 (22.1) 19 (22.6) 99 (20.1) 55 (18.3) 
 10-19 years  127 (28.9) 5 (33.3) 99 (30.8) 28 (33.3) 91 (18.5) 59 (19.6) 
 20-29 years  89 (20.2) 2 (13.3) 28 (8.7) 6 (7.1) 68 (13.8) 42 (14.0) 
 ≥30 years  69 (15.7) 3 (20.0) 46 (14.3) 10 (11.9) 83 (16.9) 48 (15.9) 
Season 452 17 321 84 488 297 
 Wet season  151 (33.4) 3 (17.6) 124 (38.6) 32 (38.1) 226 (46.3) 131 (44.1) 
 Dry season  301 (66.6) 14 (82.4) 197 (61.4) 52 (61.9) 262 (53.7) 166 (55.9) 
Duration on-going sickness 433 17 302 82 441 259 
 Median (days)  30.0 30.0 14.0 12.0 30.0 21.0 
 (inter-quartile range)  (15.0-40.0) (13.5-76.0) (9.0-21.0) (7.0-14.0) (14.0-61.0) (14.0-61.0) 
Infection intensity and case-fatality rate of VL-malaria co-infections in 
Gedarif and Sennar States (2005–2010) 
Intensity of VL infection, as determined by parasitaemia in lymph node or bone marrow 
aspirates, was directly related with the frequency of VL-malaria co-infections. Stratified by 
infection intensity, in fact, the ratio of VL-malaria co-infections was lowest in the groups 
with less severe VL (n = 339/757, 44.8% as determined in lymph node aspirates and n = 
15/259, 5.8% as determined in bone marrow aspirates) and gradually increased as VL 
infection intensified (n = 3/4, 75.0% and n = 1/5, 20.0% in lymph node and bone marrow 
aspirates, respectively, with the highest intensity) (Table 2). 
Table 2 VL-malaria co-infections, stratified by VL infection intensity, and its 
association with the overall in-hospital death, Sudan (2005–2010) 
Infection 
intensity of VL 
in aspirates 
n cases/ 
denominators 
% In-hospital 
deaths n (%) 
Discharged 
alive n (%) 
Odds 
Ratio 
95% 
Confidence 
Interval 
lymph node 377/824  21 790   
+1 339/757 44.8 18 (85.7) 727 (92.0) 1  
+2 24/44 54.5 2 (9.5) 41 (5.2) 1.97 0.44-8.78 
+3 11/19 57.9 0 19 (2.4) 1.00 0.99-1.00 
+4 3/4 75.0 1 (4.8) 3 (0.4) 13.46 1.34-135.77* 
bone marrow 16/264  13 247   
+1 15/259 5.8 11 (84.6) 244 (98.8) 1  
+2 1/5 20.0 2 (15.4) 3 (1.2) 14.79 2.24-97.74* 
*P-value <0.10 based on Fisher Exact Probability tests. 
During hospitalization, 14 co-infected patients died, resulting in an overall case-mortality rate 
of 3.5%. A similar case-fatality rate was found among the controls (3.1%, n = 27) (OR: 1.13; 
95% CI: 0.59-2.17), indicating that concomitant malaria did not represent a risk factor for 
poor prognosis. When stratified by malaria treatment, in-hospital fatalities clustered amongst 
co-infected patients treated with artemether and quinine, whose mortality risk was 13-fold 
(OR: 13.34; 95% CI: 0.77-229.85) and 15-fold (OR: 15.35; 95% CI: 0.81-289.33) higher, 
respectively, than in patients receiving artesunate + SP (Table 3). Patients with a high density 
of Leishmania parasites were overrepresented among those who died, confirming previous 
findings, whereby high intensities of VL infection increased the mortality risk [30]. Here, 
patients harboring high numbers of Leishmania parasites in their lymph node or bone marrow 
were found to be 13 (OR: 13.46; 95% CI: 1.34-135.77) and 15 (OR: 14.79; 95% CI: 2.24-
97.74) times more likely to die, respectively (Table 2). 
Table 3 VL-malaria co-infections, stratified by malaria treatment, and their association 
with in-hospital death, Sudan (2005–2010) 
Malaria treatment n in-hospital fatalities / 
denominator 
% Odds 
Ratio 
95% Confidence 
Interval 
Artesunate + SP 0/118 0 1  
Artemether 10/186 5.4 13.34 0.77-229.85* 
Quinine 4/69 5.8 15.35 0.81-289.33* 
Artesunate 0/15 0 - - 
Artemether + 
lumefantrine 
0/9 0 - - 
*P-value <0.10 based on Fisher Exact Probability tests. For the statistical analysis, a value of 
0.5 was added to each variable to ensure calculation of OR and 95% CI. 
Risk factors for VL-malaria co-infections in Gedarif and Sennar States (2005–
2010) 
Associations between demographic and clinical variables and the co-infection, as described 
by univariate analysis, are summarized in Table 4. Gender and age were identified as risk 
factors for the VL-malaria co-infection. Significant associations were also found to link the 
co-infected patients with the treatment center in which they have been hospitalized. Neither 
the rainy season nor the intake of anti-malarial drugs prior to hospitalization significantly 
altered the risk for VL patients of acquiring malaria. Malnourishment was relatively more 
common among cases, resulting in a positive association between severe malnutrition and the 
co-infection (OR: 2.21; 95% CI: 1.01-4.85). A similar positive association was found with 
moderately (OR: 1.73; 95% CI: 1.32-2.28) or severely anemic patients (OR: 1.50; 95% CI: 
0.99-2.28). The likelihood of being diagnosed with concomitant VL and malaria decreased as 
spleen size increased: patients with massive splenomegaly (spleen size ≥6 cm below the 
costal margin) were found to be more than twice less likely to be co-infected (OR: 0.38; 95% 
CI: 0.26-0.55) compared with patients with no or minor spleen enlargement. In some patients, 
malaria displayed an exacerbating, although not significant, effect on VL infection, as 
revealed by the increased number of Leishmania parasites observed in their lymph node or 
bone marrow aspirates. Finally, while hepatomegaly was less frequently observed in co-
infected patients compared to mono-infected patients (OR: 0.29; 95% CI: 0.18-0.48), 
jaundice (OR: 2.85; 95% CI: 1.43-5.66) and, particularly, weight loss (OR: 3.04; 95% CI: 
2.37-3.90) were more commonly reported among co-infected cases. 
Table 4 Univariate analysis of characteristics associated with VL-malaria co-infections, Sudan (2005–2010) 
Variable Cases n (%) Controls n (%) Crude Odds Ratio 95% Confidence Interval 
Gender 404 870   
Male 212 (52.5) 501 (57.6) 1  
Female 192 (47.5) 369 (42.4) 1.23 0.97-1.56* 
Age 400 853   
<5 years 120 (30.0) 176 (20.6) 1.53 1.05-2.24* 
5-9 years 77 (19.3) 180 (21.1) 0.96 0.64-1.44 
10-19 years 92 (23.0) 225 (26.4) 0.92 0.62-1.35 
20-29 years 50 (12.5) 135 (15.8) 0.83 0.53-1.30 
≥30 years 61 (15.3) 137 (16.1) 1  
Treatment center 404 882   
Gedarif Teaching Hospital 18 (4.4) 450 (51.0) 1  
Tabarakallah Hospital 84 (20.8) 237 (26.9) 8.86 5.20-15.10* 
AlˋAzaza kala-azar Clinic 302 (74.8) 195 (22.1) 38.72 23.38-64.11* 
Season 398 863   
Dry season 232 (58.3) 528 (61.2) 1  
Wet season 166 (41.7) 335 (38.8) 1.13 0.89-1.44 
Previous anti-leishmanial treatment 389 860   
No 373 (95.9) 806 (93.7) 1  
Yes 16 (4.1) 54 (6.3) 0.64 0.36-1.13 
Previous anti-malarial treatment 396 864   
No 277 (70.0) 604 (69.9) 1  
Yes 119 (30.0) 260 (30.1) 1.00 0.77-1.29 
Malnutrition 322 575   
None 262 (81.4) 497 (86.4) 1  
Mild 17 (5.3) 25 (4.3) 1.29 0.68-2.43 
Moderate 29 (9.0) 41 (7.1) 1.34 0.82-2.21 
Severe 14 (4.4) 12 (2.1) 2.21 1.01-4.85* 
Anemia degree on admission 374 725   
Median Hb (inter-quartile range) 7.0 (6.5-8.0) 8.0 (7.0-9.0)   
None-mild (Hb ≥7.3 g/dl) 182 (48.7) 445 (61.4) 1  
Moderate (Hb 5.3-7.2 g/dl) 149 (39.8) 210 (29.0) 1.73 1.32-2.28* 
Severe (Hb <5.3 g/dl) 43 (11.5) 70 (9.7) 1.50 0.99-2.28* 
Spleen size 238 563   
Median (inter-quartile range) 4.0 (2.0-6.0) 5.0 (2.0-8.0)   
0-3 cm 94 (39.5) 150 (26.6) 1  
4-5 cm 79 (33.2) 141 (25.0) 0.89 0.61-1.30 
≥6 cm 65 (27.3) 272 (48.3) 0.38 0.26-0.55* 
Infection intensity in lymph node aspirate 377 447   
+1 339 (89.9) 418 (93.5) 1  
+2 24 (6.4) 20 (4.5) 1.48 0.80-2.72 
+3 11 (2.9) 8 (1.8) 1.70 0.67-4.26 
+4 3 (0.8) 1 (0.2) 3.70 0.38-35.72 
Infection intensity in bone marrow aspirate 16 248   
+1 15 (93.8) 244 (98.4) 1  
+2 1 (6.2) 4 (1.6) 4.07 0.43-38.68 
Symptoms 404 880   
Hepatomegaly 19 (4.7) 128 (14.5) 0.29 0.18-0.48* 
Jaundice 19 (4.7) 15 (1.7) 2.85 1.43-5.66* 
Weight loss 278 (68.8) 370 (42.0) 3.04 2.37-3.90* 
*P-value <0.10 based on Person Chi-square tests 
All 11 variables associated with the VL-malaria co-infection in the univariate analysis were 
included in the multivariable models. Due to the high number of missing data in reporting 
clinical signs and symptoms, three different models were designed to explore the association 
between the selected variables and the VL-malaria co-infection: model A, in which the 
independent risk factors were identified, model B describing the association between clinical 
signs and symptoms and the co-infection and model C, which combines all variables (risk 
factors, clinical signs and symptoms) in one analysis. Model A (Table 5) shows that, after 
adjusting for the other variables included in the model, the treatment center in which co-
infected patients were hospitalized, and therefore its catchment area, remained the most 
important factor associated with the risk of being co-infected. After adjusting for the other 
variables included in the model, gender and age lost their statistical significance. The variable 
age, however, was kept in the model as it significantly increased its fit. 
Table 5 Model A: Multivariate analysis of risk factors for VL-malaria co-infections 
among VL patients, Sudan (2005–2010) 
n = 1253 Odds Ratio 95% Confidence Interval P-value 
Treatment center    
Gedarif Teaching Hospital 1 - <0.001 
Tabarakallah Hospital 9.88 5.57-17.55 <0.001 
Al`Azaza kala-azar Clinic 44.85 25.89-77.71 <0.001 
Age    
<5 years 1.26 0.81-1.97 0.305 
5-9 years 1.01 0.63-1.62 0.972 
10-19 years 1.31 0.83-2.09 0.246 
20-29 years 1.06 0.62-1.80 0.842 
≥30 years 1 - 0.608 
In model B (Table 6), logistic regression was performed on the sub-cohort of patients for 
whom symptoms, besides other features, were reported. After adjusting for the other 
variables included in the model, malnutrition lost its statistical significance and was therefore 
excluded from the model. The variable hepatomegaly also lost most of its significance, but a 
slightly negative association could still be recognized (OR: 0.52; 95% CI: 0.26-1.01). The 
risk for VL patients of developing jaundice (OR: 2.52; 95% CI: 1.04-6.09) or undergoing 
weight loss (OR: 2.46; 95% CI: 1.72-3.50), on the other hand, was doubled by the 
concomitancy of malaria. 
Table 6 Model B: Multivariate analysis of clinical signs and symptoms associated to VL-
malaria co-infections, Sudan (2005–2010) 
n = 690 Odds Ratio 95% Confidence Interval P-value 
Symptoms    
Hepatomegaly 0.52 0.26-1.01 0.052 
Jaundice 2.52 1.04-6.09 0.041 
Weight loss 2.46 1.72-3.50 <0.001 
Spleen size    
0-3 cm 1 - 0.007 
4-5 cm 0.90 0.60-1.36 0.629 
≥6 cm 0.53 0.35-0.81 0.003 
Anemia    
None – mild (Hb ≥7.3 g/dl) 1 - 0.440 
Moderate (Hb 5.3-7.2 g/dl) 1.58 1.10-2.28 0.013 
Severe (Hb <5.3 g/dl) 1.10 0.63-1.93 0.737 
Massive splenomegaly was less common among co-infected patients (OR: 0.53; 95% CI: 
0.35-0.81), who instead suffered frequent exacerbations of their anemic status, as observed in 
the group with moderate anemia (OR: 1.58; 95% CI: 1.10-2.28). 
Combining all variables in one model (model C, Table 7) resulted in the loss of significance 
for all variables, except the one involving the treatment center, which possibly displayed a 
confounding effect on all other associations. The model confirmed a key role for this 
variable, which led to an 8- and 42- fold different likelihood of being co-diagnosed with VL 
and malaria in Tabarakallah Hospital (OR: 8.02; 95% CI: 3.68-17.46) and Al`Azaza kala-azar 
Clinic (OR: 41.66; 95% CI: 20.01-86.72), respectively, compared to Gedarif Teaching 
Hospital. 
Table 7 Model C: Multivariate analysis of risk factors, clinical signs and symptoms 
associated to VL-malaria co-infections, Sudan (2005–2010) 
n = 690 Odds Ratio 95% Confidence Interval P-value 
Treatment center    
Gedarif Teaching Hospital 1 - <0.001 
Tabarakallah Hospital 8.02 3.68-17.46 <0.001 
Al`Azaza kala-azar Clinic 41.66 20.01-86.72 <0.001 
Spleen size    
0-3 cm B.C.M. 1 - 0.706 
4-5 cm B.C.M. 1.20 0.76-1.90 0.428 
≥6 cm B.C.M. 1.15 0.71-1.86 0.563 
Anemia    
None – mild (Hb ≥ 7.3 g/dl) 1 - 0.219 
Moderate (Hb 5.3-7.2 g/dl) 1.28 0.85-1.94 0.239 
Severe (Hb <5.3 g/dl) 0.74 0.39-1.40 0.356 
MSF’s dataset 
Between November and December 1998, 516 primary-VL cases were diagnosed in the MSF 
kala-azar treatment centers of Um-el-Kher and Kassab. Positive DAT results were obtained 
for most patients (n = 440, 86%), whose diagnosis was occasionally confirmed, as for all 
patients with borderline DAT titers (from 1:400 to 1:6400), by parasitological evidence in 
lymph node or spleen aspirates (n = 140, 27%). Microscopy-confirmed malaria was co-
diagnosed in 89 VL patients (17.2%), 10 of whom died (11.2%). Given the lower case-
fatality rate among controls (2.8%), here co-infections significantly increased the mortality 
risk of VL patients by nearly four and half fold (OR: 4.38; 95% CI: 1.83-10.48) (Table 8). Of 
the 10 co-infection-related fatalities, 4 were considered to be caused by anemia, and one by 
cerebral malaria. Although no clear differences in the median hemoglobin level of VL-
malaria co-infected patients (7.5 g/dl) versus the mono-infected VL patients (8.2 g/dl) could 
be detected, the proportion of patients with severe anemia (Hb <5.3 g/dl) was significantly 
higher among cases (15.7%) than among controls (5.2%) (OR: 3.44; 95% CI: 1.68-7.02). No 
other major differences in nutritional status, spleen size below the costal margin and duration 
of on-going disease prior to hospitalization were observed between co-and mono-infected 
patients, except their distribution between the two treatment centers. With more than 80% of 
the co-infection cases recorded in Um-el-Kher Hospital, the risk here, of being co-diagnosed 
with VL and malaria was nearly double (OR: 1.94; 95% CI: 1.10-3.41) than at Kassab 
Hospital. 
Table 8 Characteristics of the malarial VL co-infected patients versus the non-malarial 
VL patients enrolled in the MSF’s clinical trial at Um-el-Kher and Kassab Hospitals, 
Sudan (1998) 
Variable Cases n (%) Controls n (%) Crude Odds 
Ratio 
95% Confidence 
Interval 
Age 89 427   
Median (years), (interquartile range) 7 (4–14) 10 (6–17)   
Treatment center 89 427   
Kassab Hospital 17 (19.1) 134 (31.4) 1  
Um-el-Kher Hospital 72 (80.9) 293 (68.6) 1.94 1.10-3.41* 
Fatal outcome 89 427   
No 79 (88.8) 415 (97.2) 1  
Yes 10 (11.2) 12 (2.8) 4.38 1.83-10.48* 
Hb level 89 427   
Median (g/dl), (interquartile range) 7.5 (6.0-9.0) 8.2 (7.0-9.4)   
≥5.3 g/dl 75 (84.3) 405 (94.8) 1  
<5.3 g/dl 14 (15.7) 22 (5.2) 3.44 1.68-7.02* 
Nutritional status 68 299   
Mean Weigh for Height (%) 78.8 80.4   
Weight for Height Percent ≥70% 60 (88.2) 279 (93.3) 1  
Weight for Height Percent <70% 8 (11.8) 20 (6.7) 1.86 0.78-4.42 
Spleen size below the costal margin 80 389   
Median (cm), (interquartile range) 6 (3–8) 7 (4–10)   
<6 cm 33 (41.2) 144 (37.0) 1  
≥6 cm 47 (58.8) 245 (63.0) 0.84 0.51-1.37 
Duration on-going sickness 86 422   
Median (days), (interquartile range) 30 (15–60) 30 (20–60)   
<60 days 62 (72.1) 286 (67.8) 1  
≥60 days 24 (27.9) 136 (32.2) 0.81 0.49-1.36 
*P-value <0.05 based on Person Chi-square test. 
Discussion 
This is the first multicenter retrospective survey ever undertaken in the field of VL-malaria 
co-infections. The study describes the epidemiology of concomitant malaria among VL in-
patients from Gedarif Teaching Hospital, Tabarakallah Hospital and Al`Azaza kala-azar 
Clinic, eastern Sudan (2005–2010) and confirms its clinical relevance by comparing 
prevalence and mortality rates with an antecedent (1998), independently collected dataset 
from the same region (Um-el-Kher and Kassab Hospitals). Not only the risk of co-acquiring 
VL and malaria appears to be substantial in these areas, with a significant geographical 
variation, but the clinical implications deriving from being co-infected provide the evidence 
for a public health concern. Exacerbated clinical pictures and increased mortality risk, 
possibly due to inadequate antimalarial treatment, were highlighted by this survey, suggesting 
that prompt diagnosis and effective therapy of concomitant malaria is needed to ensure 
positive resolution of the VL-malaria co-infection. 
Ranging from 3.8 to 60.8% and with a median of 26.2%, the prevalence of malaria co-
infection among VL surveyed patients (2005–2010) confirms the frequent superimposing of 
the two diseases in rural areas of Gedarif and Sennar States. Although these estimates may be 
higher than expected, based on the local malaria transmission rates, similar figures have been 
found in the MSF’s dataset from Um-el-Kher and Kassab Hospitals, where 11.3% and 19.7%, 
respectively, of the VL patients enrolled in the clinical trial (1998) were positive for malaria. 
Again at Um-el-Kher Hospital, clinical studies conducted between January 2004 and early 
2005 revealed that 15% of pregnant VL women enrolled in the trial [31] and 31% of 
Ambisome-treated VL patients [6] were co-diagnosed with malaria, while a 4.8% rate was 
found in Kassab (2005–2006) [32], where the malaria prevalence is notoriously lower. In 
agreement with previous observations performed at Amudat Hospital, Uganda (2000–2006) 
[1], where a co-infection rate of 19% was reported using the same criteria as here, the 
frequent co-occurrence of malaria in VL patients suggests that these patients may have 
increased susceptibility towards the malarial infection, possibly due to a VL-promoted 
impairment of the immune system. The clustering of most co-infection diagnoses in 
Al`Azaza kala-azar Clinic (74.8%), however, followed by Tabarakallah Hospital (20.8%) and 
Gedarif Teaching Hospital (4.4%) is rather unexpected. In Gedarif Teaching Hospital, only 
3.8% of the VL-confirmed patients were co-diagnosed with malaria, a figure which may be 
explained by its function as Regional Reference Hospital, besides the low malaria burden 
found in this urban area. Difficult cases encountered in rural hospitals and referred to Gedarif 
Teaching Hospital, usually received, prior to admission to the Regional Hospital, a full course 
of anti-malarial treatment to exclude malaria as a possible complication. This may therefore 
have resulted in a lower percentage of VL patients having malaria on hospital admission. The 
longer disease duration described among VL patients hospitalized in Gedarif Teaching 
Hospital compared to the other two study sites and their villages of origin seem to confirm 
that a large number of these patients may not have presented to this hospital as a first-line 
action. If, therefore, a higher malaria-VL co-infection rate is to be expected in rural hospitals 
of Gedarif and Sennar State, the figure obtained in Al`Azaza kala-azar Clinic (60.8%), 
appears to somehow overestimate the burden posed by this co-morbidity. Given that higher 
malaria rates, favored by the proximity with the river and natural reserve, might have locally 
occurred, poor quality of malaria diagnosis in Al`Azaza kala-azar Clinic cannot be excluded. 
Concomitant malaria partly exacerbated the clinical picture of VL patients, who presented 
with more frequent emaciation, icterus and moderate anemia. Two scenarios may be 
postulated: co-infected patients may either have suffered from malaria-associated symptoms 
which, in addition to the VL ones, have caused deterioration of their clinical condition and/or 
have run an exacerbated course of VL due to concomitant malaria, in which case symptoms 
may be related to VL rather than to malaria. If this latter hypothesis may find its rationale in 
the increased number of Leishmania parasites observed in aspirates of co-infected patients, 
the first speculation may be supported by the peculiar symptom pattern. Jaundice, in fact, is 
rarely described among VL patients, while it is not uncommon in P. falciparum malaria [33]. 
Weight loss and anemia, on the other hand, are hallmark of both VL and malaria and an 
increased severity of the anemic status, as observed in co-infected patients, may therefore be 
the result of an added effect displayed by both diseases on the polyparasitized host. In 
apparent contradiction is the finding, whereby co-infected patients suffered from less severe 
hepato-splenomegaly. Suggesting a less advanced state of the diseases in the co-infected 
patients, the result may be explained by their earlier hospitalization compared to mono-
infected VL patients. Patients with concomitant VL and malaria, in fact, presented at hospital 
nearly 10 days earlier, on average, than those with only VL, possibly due to their more severe 
symptomatology. Importantly, this may have also had positive implications for their 
prognosis, which was found to be similar to the controls’ one. 
In antithesis to the positive resolution of VL-malaria co-infections during the 2005–2010 
survey, is the significantly higher fatality rate (P-value 0.001) associated with co-infected 
patients enrolled by MSF at Um-el-Kher and Kassab Hospital in 1998. During this trial, co-
infected patients were nearly four and half times more likely to die compared to the VL 
mono-infected patients, whose mortality (2.8%) on the other hand, compares well to what 
found in the most recent survey (3.1%). Different anti-malarial regimen were used within the 
two study groups: SP and quinine in 1998 for uncomplicated and severe malaria, 
respectively; artemisinin derivatives (alone or in combination) and more rarely quinine 
between 2005 and 2010. Sudan’s choice to introduce artemisinin-based combination 
therapies (ACTs) for treatment of uncomplicated and severe malaria was implemented 
nation-wide in 2004 [34], following increasing evidence of resistance against chloroquine, SP 
and quinine, for which failure rates up to 76.9, 16.1 and 16.7%, respectively, were recorded 
in eastern Sudan prior to ACT era [35-38]. The 11.2% mortality rate of VL-malaria co-
infections observed in 1998 at Um-el-Kher Hospital may therefore have partially resulted 
from treatment failures attributable to either SP or quinine, besides the more severe malaria 
course in patients receiving quinine. In fact, no major differences for age, median Hb level, 
nutritional status, spleen size and duration of on-going disease distinguished the co-infected 
patients’ group at Um-el-Kher and Kassab Hospitals from the one surveyed in 2005–2010 
and from its relative controls. The only exception is to be found in the significantly higher 
number of VL patients who developed severe anemia when co-infected with malaria, 
similarly to what was observed during the 2005–2010 survey, though to a less extent. Hence, 
concomitant malaria may not only cause aggravation of VL patients’ clinical condition, but it 
may also result in a poorer prognosis, if failed to be treated. Among co-infected patients 
surveyed in 2005–2010, an increased mortality risk, not ascribable to differences in 
Leishmania intensities, was observed when quinine (P-value 0.07) and artemether (P-value 
0.04) were administered as antimalarials, suggesting either increased malaria severity or 
inadequate drug treatment. 
The population surveyed within this study consists of VL patients residing in over 300 
different villages, mainly located in Gedarif and Sennar States. Within these districts, 
Tabarakallah Hospital and Al`Azaza kala-azar Clinic are two rural hospitals receiving 
patients from some of the worst-affected villages. It should be noted, however, that the cohort 
of VL patients surveyed here might be sub-representative of the local VL community, as the 
number of VL-related hospitalizations carried out by the two MSF’s treatment centers in 
Gedarif Sate (>4000 per year between 1997 and 1999 [22]) exceeds by far the one recorded 
by the three study hospitals (1324 in total between 2005 and 2010). Other limitations apply to 
this study, the most important ones being the lack of non-VL malaria infected patients and the 
quality of diagnosis. Unlike VL, uncomplicated malaria infections are commonly treated on 
an outpatient basis in hospitals, clinics or simple practices, resulting in few data being 
systematically recorded by the different facilities. Moreover, malaria patients are rarely found 
in VL-dedicated hospitals, such as those surveyed in this study. This resulted into the lack of 
valid malaria controls, essential to investigate whether VL might predispose or rather protect 
towards a malarial attack and whether it might influence its course and clinical presentation. 
In absence of quality control, quality of diagnosis, remains questionable. Variable outcomes, 
as documented in medical records, may have suffered from poor standardization, due to the 
different techniques implemented by clinicians in the different treatment centers and the 
possible involvement of different health workers in filling these files. 
Conclusion 
Based on the results of this study, we conclude that VL patients living in areas with unstable 
seasonal malaria, such as eastern Sudan, are highly exposed to the risk of developing 
concomitant malaria. Large variation in the geographical distribution of co-infection cases 
highlights the presence of environmental and/or social factors, whose identity and relevance 
in the risk of co-acquiring VL and malaria still remain to be elucidated. Clinical concerns 
should arise when the two diseases co-occur in the same patients, as significant exacerbation 
of their clinical condition was observed, along with an increased mortality risk, possibly 
associated with inappropriate anti-malarial treatment. Local health care policies should take 
into account the high co-infection burden borne by VL foci with unstable malaria, by 
recommending systematic malaria screening for all VL patients and ACTs for treatment of 
malaria. 
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